

Supplementary information

Charge Reversal Hairpin Peptides Modified Synergy Therapeutic Nanoplatfoms for Tumor Specific Drug Shuttling

Zhechen Fan, †^a Zhongsheng Ji, †^a Feng Zhang,^a Peng Luo,^a Huaqing Zhang,^a

Jianping Zhou,^{*a} Hao Cheng^{*a} and Yang Ding^{*a,b}

^a State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China

Pharmaceutical University, Nanjing 210009, China. E-mail: dydszyzf@163.com,

chenghaocloud@163.com and zhoujianping@cpu.edu.cn

^b State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou

Medical University, Guiyang 550014, China

† These authors contributed equally to this work.




Fig. S1 Analysis of drug loading of GCP_{DOX}. (a) UV spectra of the free drugs obtained by different amounts of DOX under the condition that GO is fixed at 1mg. (b) Standard

curve measured by ultraviolet spectrophotometry at 480 nm with various concentration of DOX (5 to 125 $\mu\text{g}/\text{mL}$).




Fig. S2 Study of the storage stability of GCP_{DOX} . The change in the particle size and PDI of GCP_{DOX} nanoparticles at 4 $^{\circ}\text{C}$ for 30 d.




Fig. S3 Study of the serum stability of GCP_{DOX} . (a) The change in the particle size and PDI of GCP_{DOX} nanoparticles at 10% FBS for 24 h. (b) The change in the entrapment efficiency of GCP_{DOX} nanoparticles at 10% FBS for 24 h.




Fig. S4 Cellular uptake of GP_{DOX} nanoparticles by 4T1 cells during the predetermined time intervals at pH 7.4. Nuclei (blue) were stained with DAPI, and DOX was shown in red.




Fig. S5 *In vivo* safety profile. Body weight change of the study groups (n=8).